School of Pharmacy, Room 801 N, Lo Kwee-Seong Integrated Biomedical Sciences Building, Faculty of Medicine, The Chinese University of Hong Kong, Area 39, Shatin, New Territories, Hong Kong SAR, China.
J Biomed Sci. 2013 Dec 20;20(1):99. doi: 10.1186/1423-0127-20-99.
Multidrug resistance (MDR) is a major obstacle to successful cancer treatment. It is often associated with an increased efflux of a variety of structurally unrelated anticancer drugs by ATP-binding cassette (ABC) transporters including P-gp, ABCG2 and MRP1. MicroRNAs (miRNAs) are small non-coding RNAs that govern posttranscriptional regulation of target genes by interacting with specific sequences in their 3' untranslated region (3'UTR), thereby promoting mRNA degradation or suppressing translation. Accumulating evidence suggests that alterations in miRNAs contribute to resistance to anticancer drugs. While miRNAs are well-known to be dysregulated in cancer, recent literature revealed that miRNA levels in biological samples may be correlated with chemotherapy response. This review summarized the coordinated network by which miRNA regulated MDR transporters. The usefulness of miRNAs as prognostic biomarkers for predicting chemotherapeutic outcome is discussed. MiRNAs may also represent druggable targets for circumvention of MDR.
多药耐药性（MDR）是癌症治疗成功的主要障碍。它通常与 ABC 转运蛋白（如 P-糖蛋白、ABCG2 和 MRP1）将多种结构上无关的抗癌药物的外流增加有关。MicroRNAs（miRNAs）是小的非编码 RNA，通过与 3'非翻译区（3'UTR）中的特定序列相互作用，对靶基因进行转录后调控，从而促进 mRNA 降解或抑制翻译。越来越多的证据表明，miRNAs 的改变导致了对抗癌药物的耐药性。虽然 miRNA 在癌症中被广泛认为是失调的，但最近的文献表明，生物样本中的 miRNA 水平可能与化疗反应相关。本文综述了 miRNA 调节 MDR 转运蛋白的协调网络。讨论了 miRNA 作为预测化疗结果的预后生物标志物的有用性。miRNA 也可能代表克服 MDR 的可用药靶。
